The same gap appears in EV/EBITDA, where a 24.3x trailing figure collapses to 11.2x forward, suggesting the market expects either a substantial EBITDA step-up or is simply anchoring on depressed trailing results distorted by the 2025Q2 loss quarter. At P/B 3.60, HCSG already trades at nearly twice ABM's 1.90 despite posting a lower ROIC of 6.1% versus ABM's 7.5%, which may indicate investors are paying for margin-normalization optionality rather than demonstrated return superiority. If the raised $535M-$545M revenue guidance proves aggressive, the downside math on the forward multiple appears unfavorable.

Critically, the recovery still sits below the 9.6% ROIC printed in 2025Q3, so the current 6.1% reads more like normalization than a new plateau, and the driver appears to be margin recovery rather than capital efficiency given asset turnover has moved only from 0.53 to 0.57 over ten quarters. The spread between 4.7% ROE and 3.0% ROA confirms returns are almost entirely asset-driven rather than leverage-amplified, since the 0.02 debt-to-equity ratio contributes virtually nothing to equity returns. Investors should treat the ROIC trajectory as the cleaner test of whether the regulatory-specialization moat actually earns an economic spread, independent of the buyback-driven EPS optics.

Because DPO has remained anchored in a narrow 16-21 day band across the full ten-quarter window, the DSO improvement reads as genuine collection discipline rather than supplier-financing float, which meaningfully strengthens the cash conversion story. That said, 63 days remains elevated in absolute terms and is consistent with a customer base of thinly capitalized mid-size operators, so the favorable trajectory should be stress-tested against any allowance-for-doubtful-accounts build. Asset turnover's gradual climb from 0.53 to 0.57 corroborates modestly improving revenue per dollar of assets, though the low absolute level reflects the labor-service rather than capital-intensity profile of the model.

Total debt has contracted roughly 72% while cash grew about fivefold, meaning the leverage profile reflects deliberate deleveraging rather than covenant pressure, and refinancing risk appears effectively nil. The historical D/EBITDA swings from 0.31 to 19.95 are almost entirely earnings-driven rather than debt-driven, a pattern that should caution analysts against reading leverage ratios as a stability signal here; the volatility lives in the denominator. With near-zero financial leverage, the balance sheet functions as shock absorption against labor-cost or regulatory shocks rather than as a return-multiplying tool, which structurally caps the ROE ceiling.

The identical current and quick ratios confirm inventory is functionally immaterial, consistent with DIO holding near 4 days, so the real working-capital exposure sits in receivables rather than stock — a distinction that reframes where stress would actually surface. Investors should note the buffer is not static: roughly $123M of buybacks over ten quarters means surplus liquidity is being actively deployed, so prospective stress capacity depends on operating cash flow staying ahead of the repurchase pace. Any deterioration in the DSO trend would compress both liquidity and earnings simultaneously, given receivables appear to be the single largest liquid asset class on the balance sheet.